Condition
Crohn's Disease
Clear, practical articles to help you understand Crohn's Disease symptoms, medications, flares, nutrition, and everyday disease management. Browse our articles below.
Tremfya vs Stelara for Crohn's Disease: GALAXI Trial
Tremfya and Stelara are both Johnson & Johnson biologics for moderate-to-severe Crohn's disease, and they present a rare scenario where a manufacturer's newer drug is being compared head-to-head with its predecessor. Stelara has been the workhorse IL-12/23 biologic in IBD since its Crohn's approval in 2016. Tremfya is a newer p19-selective IL-23 biologic that J&J brought to IBD markets starting in 2024. The GALAXI 2 and GALAXI 3 trials directly compared these two drugs in Crohn's, and the results favor Tremfya on endoscopic endpoints. This guide walks through what Crohn's patients need to know when weighing the tremfya vs stelara crohn's decision.
Tremfya vs Remicade for Crohn's: Comparing Biologics
Tremfya and Remicade are two of the biologics Crohn's patients commonly consider when Remicade has lost effect or when starting a first biologic. Remicade has been the anti-TNF standard for more than two decades. Tremfya is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2024 based on the GALAXI trial program. The drugs take very different mechanistic approaches and offer different administration options, which shapes the decision for many Crohn's patients. This guide walks through the tremfya vs remicade crohn's comparison.
Tremfya vs Omvoh for Crohn's Disease: Key Differences
Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, each newly approved for the indication. Tremfya gained Crohn's approval in March 2025 based on GALAXI-2 and GALAXI-3, with the GRAVITI trial supporting a fully subcutaneous induction option. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh administration flexibility and active-comparator trial design. This guide walks through the tremfya vs omvoh crohn's comparison.
Tremfya vs Humira for Crohn's Disease: Key Differences
Tremfya and Humira represent two different eras in Crohn's biologic therapy. Humira is a fully human anti-TNF biologic that has been a Crohn's staple since 2007. Tremfya is an IL-23 p19-selective biologic that gained Crohn's approval in 2024 and uniquely offers both subcutaneous and intravenous induction pathways. Patients comparing these drugs often weigh mechanism, administration flexibility, and the strength of the available trial evidence. This guide walks through the tremfya vs humira crohn's decision.
Tremfya vs Entyvio for Crohn's Disease: How They Compare
Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and patients often compare them when prioritizing safety or looking for alternatives to systemic TNF blockade. Tremfya is an IL-23 p19-selective biologic with strong endoscopic data from the GALAXI and GRAVITI trials. Entyvio is gut-selective and acts almost exclusively on the intestines. Both offer meaningful safety advantages over anti-TNFs, but they work through very different mechanisms. This guide walks through the tremfya vs entyvio crohn's comparison.
Skyrizi vs Tremfya for Crohn's Disease: Which Is Right?
Skyrizi and Tremfya are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, made by competing manufacturers (AbbVie and Johnson & Johnson). Both drugs belong to the same mechanism class and target the same cytokine subunit, so the skyrizi vs tremfya crohn's comparison often comes down to trial data, administration options, and maintenance convenience. This guide walks through the key differences to help you discuss the decision with your GI.
Skyrizi vs Stelara for Crohn's Disease: SEQUENCE Trial Results
Skyrizi and Stelara are two interleukin-pathway biologics for moderate-to-severe Crohn's disease, and until recently the choice between them was largely mechanistic speculation. That changed with the SEQUENCE trial, a rare head-to-head randomized study that directly compared risankizumab (Skyrizi) with ustekinumab (Stelara) in Crohn's patients who had failed an anti-TNF. The results have reshaped how many gastroenterologists think about IL-23 targeting and have moved Skyrizi toward the front of the line for biologic-experienced Crohn's disease. This guide walks through the SEQUENCE findings and the practical decisions patients need to make with their GI.
Skyrizi vs Remicade for Crohn's Disease: Which Is Better?
Skyrizi and Remicade represent two very different eras of Crohn's biologic therapy. Remicade (infliximab) has been the anti-TNF workhorse since its approval in the late 1990s. Skyrizi (risankizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2022 and has quickly gained market share. Patients often compare these drugs when starting biologic therapy for the first time or when weighing alternatives after Remicade has lost effect. This guide walks through the evidence for the skyrizi vs remicade crohn's decision.
Skyrizi vs Omvoh for Crohn's Disease: A Comparison
Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease. Skyrizi gained Crohn's approval in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh maintenance dosing, trial design, and GI familiarity with each drug. This guide walks through the skyrizi vs omvoh crohn's comparison.
Skyrizi vs Humira for Crohn's Disease: Comparing Options
Skyrizi and Humira are both AbbVie biologics for moderate-to-severe Crohn's disease, and they represent very different mechanisms. Humira is the long-established anti-TNF standard with more than two decades of use in IBD. Skyrizi is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2022 and has quickly become a prescribing favorite. For patients weighing a first-line biologic, the skyrizi vs humira crohn's decision often comes down to mechanism, administration preferences, and data from anti-TNF experienced cohorts. This guide walks through the evidence Crohn's patients need to discuss with their gastroenterologist.
Skyrizi vs Entyvio for Crohn's Disease: A Patient Guide
Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and they take very different approaches to quieting gut inflammation. Skyrizi is an IL-23 p19-selective biologic that acts on the immune system more broadly while still avoiding TNF blockade. Entyvio is gut-selective and acts almost exclusively on the intestines. Both are increasingly common choices for patients who have failed an anti-TNF or want to avoid systemic immunosuppression from the start. This guide walks through the evidence Crohn's patients need for the skyrizi vs entyvio crohn's decision.
Omvoh vs Stelara for Crohn's Disease: Key Differences
Omvoh and Stelara are two IL-23 pathway biologics for moderate-to-severe Crohn's disease, but they target the pathway at different points. Stelara blocks both IL-12 and IL-23 through the shared p40 subunit. Omvoh selectively blocks only IL-23 through its p19 subunit. The scientific rationale behind p19 selectivity is that IL-23 is the dominant driver of Crohn's inflammation while IL-12 plays broader immune roles that may not need blocking. Omvoh's VIVID-1 trial directly compared mirikizumab with ustekinumab as an active comparator, giving patients meaningful head-to-head data. This guide walks through the omvoh vs stelara crohn's decision.